Hydroxychloroquine
Small molecule targets ACE2, TLR2, TLR4, TLR7, TLR9 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PLAQUENIL | — | 1955-04-18 | fda.gov ↗ |
Trials 336 · started per year
Also used as a comparator or background therapy in 146 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04809623 Background | Sep 2021 → Oct 2022 | cutaneous lupus erythematosus | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT04461353 Comparator | Jun → Aug 2020 | COVID-19 | Pulmoquine Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04976465 Background | Jan 2018 → Jul 2025 overdue | pregnancy disorder, systemic lupus erythematosus | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04390152 Comparator | Jan 2020 → Mar 2022 | acute respiratory distress syndrome | BioXcellerator | Terminated | No outcome recorded |
| Phase 1/2 | NCT02756546 Comparator | Sep 2014 → Sep 2015 | systemic lupus erythematosus | Cairo University | Completed | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07557927 Comparator | Apr 2026 → Sep 2028 expected | discoid lupus erythematosus | Kunming Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06862284 Comparator | Mar 2025 → Dec 2026 expected | Sjogren syndrome | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06768294 Comparator | Jan 2025 → Jun 2026 overdue | chondrocalcinosis | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06753565 Background | Dec 2024 → Jun 2025 overdue | rheumatoid arthritis | German University in Cairo | Recruiting | No outcome recorded |
| Phase 2 | NCT06519617 Comparator | Jul 2024 → Dec 2026 expected | Sjogren syndrome | Qingwen Tao | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06640309 Background | Dec 2023 → Jun 2025 overdue | rheumatoid arthritis | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2 | NCT05942911 Comparator | Nov 2023 → Oct 2024 | rheumatoid arthritis | Incannex Healthcare Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT05016297 Comparator | Jul 2022 → Aug 2024 | Sjogren syndrome | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05447520 Background | Dec 2021 → Dec 2022 | rheumatoid arthritis | Noha Mansour | Completed | No outcome recorded |
| Phase 2 | NCT04275778 Comparator | Jul 2021 → Oct 2024 | primary antiphospholipid syndrome | Assistance Publique - Hôpitaux de Paris | Withdrawn | No outcome recorded |
| Phase 2 | NCT04605588 Comparator | Dec 2020 → Jan 2021 | COVID-19 | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2 | NCT04860284 Comparator | Sep 2020 → Feb 2021 | COVID-19 | Makerere University | Unknown | No outcome recorded |
| Phase 2 | NCT04459702 Background | Jul 2020 → Jul 2021 | COVID-19, severe acute respiratory syndrome | ProgenaBiome | Withdrawn | No outcome recorded |
| Phase 2 | NCT04575558 Background | Jun → Sep 2020 | COVID-19 | Latin American Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT04390061 Background | Jun → Sep 2020 | COVID-19, interstitial lung disease | Marche Polytechnic University | Unknown | No outcome recorded |
| Phase 2 | NCT04373044 Background | May 2020 → May 2021 | COVID-19 | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT04475588 Background | May → Jul 2020 | COVID-19, acute respiratory distress syndrome, cytokine release syndrome | Biocon Limited | Completed | No outcome recorded |
| Phase 2 | NCT04374539 Comparator | Apr 2020 → Jun 2021 | COVID-19 | Fundacion Clinic per a la Recerca Biomédica | Terminated | No outcome recorded |
| Phase 2 | NCT04350281 Comparator | Apr → Jul 2020 | COVID-19 | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT04343768 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04329923 Comparator | Apr → Nov 2020 | COVID-19 | Ravi Amaravadi, MD | Terminated | No outcome recorded |
| Phase 2 | NCT04322396 Comparator | Apr 2020 → Feb 2021 | COVID-19 | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Terminated | No outcome recorded |
| Phase 2 | NCT04332094 Background | Apr 2020 → Jun 2021 | COVID-19 | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04366089 Background | Mar → Oct 2020 | COVID-19, viral pneumonia | Roberto Poscia MD, PhD | Unknown | No outcome recorded |
| Phase 2 | NCT04307693 Comparator | Mar → Apr 2020 | COVID-19 | Asan Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03863405 Background | Jan 2019 → Jan 2020 | rheumatoid arthritis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT03636152 Comparator | Dec 2018 → Jan 2024 | atherosclerosis, chronic kidney disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT03030118 Comparator | Dec 2017 → Jun 2024 | systemic lupus erythematosus | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03344172 Background | Dec 2017 → Apr 2019 | pancreas disorder | Nathan Bahary, MD | Terminated | No outcome recorded |
| Phase 2 | NCT03283566 Comparator | Oct 2017 → May 2020 | chronic pancreatitis, diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02942381 Comparator | Sep 2016 → Jan 2018 | IgA glomerulonephritis | Peking University First Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01946880 Background | Nov 2013 → Jul 2019 | systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT01067417 Comparator | Jun 2008 → Feb 2011 | HIV infectious disease | Medical Research Council | Unknown | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT05678335 Comparator | Feb → Dec 2023 | Sjogren syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05671497 Background | Nov 2022 → Oct 2024 | rheumatoid arthritis | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT04712279 Comparator | Jan → Mar 2021 | COVID-19 | Corpometria Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT04573153 Background | Sep 2020 → May 2022 | COVID-19 | ScandiBio Therapeutics AB | Terminated | No outcome recorded |
| Phase 2/3 | NCT04395170 Background | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
| Phase 2/3 | NCT04443725 Background | Jul → Oct 2020 | COVID-19 | Cairo University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04434248 Comparator | Apr → Jul 2020 | COVID-19 | Chromis LLC | Unknown | No outcome recorded |
| Phase 2/3 | NCT04475120 Comparator | Apr → Jul 2020 | COVID-19 | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 2/3 | NCT04331470 Background | Apr 2020 | COVID-19 | Fasa University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT04321616 Comparator | Mar → Aug 2020 | COVID-19, adult acute respiratory distress syndrome | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 345 trials | ||||||
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05737680 Comparator | Feb 2023 → Dec 2024 | idiopathic recurrent pericarditis | Hippocration General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04702256 Background | Dec 2021 → Dec 2031 expected | lupus nephritis, systemic lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04858633 Comparator | Mar → Jun 2021 | COVID-19 | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT05026801 Comparator | Feb → Aug 2021 | viral respiratory tract infection | Iterum Therapeutics, International Limited | Withdrawn | No outcome recorded |
| Phase 3 | NCT04981379 Comparator | Nov 2020 → Jan 2021 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 3 | NCT04403100 Comparator | Jun 2020 → Feb 2021 | COVID-19, respiratory tract infectious disorder | Cardresearch | Unknown | No outcome recorded |
| Phase 3 | NCT04501783 Comparator | May → Jul 2020 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT04352933 Comparator | May → Oct 2020 | COVID-19 | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT04411433 Comparator | May → Dec 2020 | COVID-19 | Ministry of Health, Turkey | Unknown | No outcome recorded |
| Phase 3 | NCT04383717 Comparator | May → Aug 2020 | respiratory tract infectious disorder | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT04377646 Comparator | May 2020 | COVID-19 | Military Hospital of Tunis | Unknown | No outcome recorded |
| Phase 3 | NCT04363203 Comparator | Apr 2020 → Mar 2021 | COVID-19 | Salomeh Keyhani MD | Suspended | No outcome recorded |
| Phase 3 | NCT04334148 Comparator | Apr → Dec 2020 | COVID-19 | Adrian Hernandez | Completed | No outcome recorded |
| Phase 3 | NCT04349241 Comparator | Apr → Jun 2020 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04344379 Comparator | Apr → Jun 2020 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT04315896 Comparator | Apr → Jul 2020 | COVID-19, severe acute respiratory syndrome | National Institute of Respiratory Diseases, Mexico | Completed | No outcome recorded |
| Phase 3 | NCT04329611 Comparator | Apr → Jul 2020 | COVID-19 | Dr. Michael Hill | Terminated | No outcome recorded |
| Phase 3 | NCT04341441 Comparator | Apr → Dec 2020 | COVID-19 | Henry Ford Health System | Terminated | No outcome recorded |
| Phase 3 | NCT04341727 Comparator | Apr 2020 → Apr 2021 | COVID-19 | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 3 | NCT04332991 Comparator | Apr → Jun 2020 | Orthocoronavirinae infectious disease, respiratory tract infectious disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04325893 Comparator | Apr → Jun 2020 | COVID-19 | University Hospital, Angers | Terminated | No outcome recorded |
| Phase 3 | NCT04336748 Comparator | Apr → Jul 2020 | COVID-19 | Medical University of Vienna | Withdrawn | No outcome recorded |
| Phase 3 | NCT04321278 Comparator | Mar → Jun 2020 | COVID-19, viral pneumonia | Hospital Israelita Albert Einstein | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT04408456 Comparator | Mar → Jul 2020 | COVID-19 | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT03660059 Background | Sep 2018 → Apr 2021 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT03540810 Comparator | Aug 2018 → Aug 2022 | primary antiphospholipid syndrome | University Hospital, Angers | Unknown | No outcome recorded |
| Phase 3 | NCT02930343 Comparator | Sep 2016 → Aug 2018 | rheumatoid arthritis | Jawaharlal Institute of Postgraduate Medical Education & Research | Terminated | No outcome recorded |
| Phase 3 | NCT02873936 Background | Jul 2016 → Mar 2018 | rheumatoid arthritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02444728 Comparator | Jul 2015 → Dec 2018 | thrombocytopenia | Chinese SLE Treatment And Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT02057250 Background | Mar 2014 → Feb 2015 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01941095 Background | Nov 2013 → Jul 2016 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01768572 Background | Mar 2013 → Oct 2014 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01709578 Background | Oct 2012 → Mar 2015 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01551069 Comparator | Mar 2012 → Dec 2013 | lupus erythematosus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01601028 Comparator | Jul 2011 → Aug 2013 | Sjogren syndrome, dry eye syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01256736 Background | Mar 2010 → Dec 2011 | rheumatoid arthritis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01211834 Comparator | Oct 2009 → Oct 2010 | rheumatoid arthritis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01870128 Comparator | Aug 2009 → Jun 2011 | rheumatoid arthritis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01040195 Comparator | Jun 2009 → Nov 2012 | spondyloarthropathy | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 3 | NCT00531817 Background | Oct 2007 → Jun 2009 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00720798 Background | Sep 2005 → Apr 2013 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00579878 Comparator | Mar 2001 → Mar 2010 | rheumatoid arthritis | University of Nebraska | Completed | No outcome recorded |
| Phase 434 trials | ||||||
| Phase 4 | NCT05666336 Background | Dec 2022 → Jun 2024 | systemic lupus erythematosus | Fen Li | Unknown | No outcome recorded |
| Phase 4 | NCT04981145 Comparator | Jan 2022 → Dec 2024 overdue | Sjogren syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT04779047 Comparator | Oct 2020 → Mar 2021 | COVID-19, pneumonia | October 6 University | Unknown | No outcome recorded |
| Phase 4 | NCT04435587 Comparator | Jul 2020 → Jun 2021 | COVID-19 | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT04652648 Comparator | May → Oct 2020 | COVID-19 | Bryn Mawr Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04338906 Background | May 2020 → Dec 2021 | COVID-19 | Heinrich-Heine University, Duesseldorf | Withdrawn | No outcome recorded |
| Phase 4 | NCT04359316 Background | Apr → May 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04359615 Background | Apr → May 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04350684 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04350671 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04351191 Comparator | Apr → Aug 2020 | COVID-19 | Government of Punjab, Specialized Healthcare and Medical Education Department | Terminated | No outcome recorded |
| Phase 4 | NCT04346667 Comparator | Apr → Aug 2020 | COVID-19 | Government of Punjab, Specialized Healthcare and Medical Education Department | Terminated | No outcome recorded |
| Phase 4 | NCT04362332 Comparator | Apr → Jun 2020 | COVID-19 | UMC Utrecht | Terminated | No outcome recorded |
| Phase 4 | NCT05110651 Comparator | Apr → Jul 2020 | COVID-19, end stage renal failure | Nicholas Carlson | Withdrawn | No outcome recorded |
| Phase 4 | NCT04316377 Comparator | Mar → May 2020 | COVID-19 | University Hospital, Akershus | Unknown | No outcome recorded |
| Phase 4 | NCT04077957 Background | Oct 2019 → Oct 2021 | ankylosing spondylitis | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03669367 Comparator | Jun 2019 → Jun 2022 | palindromic rheumatism | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 4 | NCT03813771 Background | Mar 2019 → Feb 2023 | rheumatoid arthritis | University of Leeds | Unknown | No outcome recorded |
| Phase 4 | NCT04066803 Background | Aug 2018 → Jul 2020 | rheumatoid arthritis | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT03449758 Background | Mar 2018 → Jul 2019 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT03122431 Comparator | Jun 2017 → Dec 2020 | cutaneous lupus erythematosus, pediatric systemic lupus erythematosus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02374021 Comparator | Jul 2016 → May 2021 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02714634 Comparator | Mar 2016 → Mar 2029 expected | rheumatoid arthritis | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 4 | NCT02644499 Comparator | Dec 2015 → Feb 2017 | rheumatoid arthritis | Jawaharlal Institute of Postgraduate Medical Education & Research | Completed | No outcome recorded |
| Phase 4 | NCT02451748 Background | Aug 2015 → Sep 2017 | rheumatoid arthritis | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT02466581 Comparator | Feb 2015 → Jul 2023 | rheumatoid arthritis | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT02433184 Comparator | Jul 2011 → Aug 2017 | rheumatoid arthritis | University of Leeds | Completed | No outcome recorded |
| Phase 4 | NCT01313208 Background | Mar 2011 → Feb 2013 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT01207739 Comparator | Sep 2010 → Oct 2013 | Borrelia infectious disease, Lyme disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00848354 Comparator | Jun 2009 → Apr 2013 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00422227 Comparator | Jun 2007 → Mar 2009 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00259610 Comparator | May 2004 → Jun 2009 | rheumatoid arthritis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT00908089 Comparator | Mar 2003 → May 2007 | rheumatoid arthritis | University of Helsinki | Unknown | No outcome recorded |
| Phase 4 | NCT00764725 Comparator | Dec 2002 → Apr 2007 | rheumatoid arthritis | Karolinska Institutet | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT07675291 Background | Jun 2026 → Dec 2028 expected | lupus nephritis | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07343635 Comparator | Feb 2026 → Jul 2027 expected | rosacea | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| — | NCT06739759 Comparator | Nov 2024 → Jun 2025 overdue | ovarian hyperstimulation syndrome | Aljazeera Hospital | Recruiting | No outcome recorded |
| — | NCT04374903 Background | Apr 2022 | — | King Hussein Cancer Center | Withdrawn | No outcome recorded |
| — | NCT05311813 Comparator | Jun → Dec 2021 | COVID-19 | Beni-Suef University | Completed | No outcome recorded |
| — | NCT04569890 Comparator | Dec 2020 → Dec 2022 | pregnancy disorder, rheumatoid arthritis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04463420 Background | Aug → Nov 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Unknown | No outcome recorded |
| — | NCT04384458 Comparator | Jul → Sep 2020 | COVID-19 | Drug Research and Development Center, Federal University of Ceara | Unknown | No outcome recorded |
| — | NCT04477083 Comparator | Jul → Aug 2020 | COVID-19, toxic maculopathy due to antimalarial drugs | Mansoura University | Unknown | No outcome recorded |
| — | NCT04438837 Comparator | Jul 2020 → Jun 2022 | COVID-19 | Rambam Health Care Campus | Unknown | No outcome recorded |
| — | NCT04668469 Comparator | Jun → Sep 2020 | COVID-19 | Benha University | Completed | No outcome recorded |
| — | NCT04380818 Background | Jun 2020 → Sep 2021 | viral pneumonia | Grupo de Investigación Clínica en Oncología Radioterapia | Unknown | No outcome recorded |
| — | NCT04371926 Comparator | Jun 2020 → Jun 2021 | COVID-19 | Texas Cardiac Arrhythmia Research Foundation | Withdrawn | No outcome recorded |
| — | NCT04394182 Background | Apr → Dec 2020 | cytokine release syndrome, viral pneumonia | Fundacion GenesisCare | Suspended | No outcome recorded |
| — | NCT04441424 Background | Apr → Jun 2020 | — | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| — | NCT04093765 Background | Nov 2018 → Dec 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| — | NCT02026232 Comparator | Mar 2012 → Dec 2022 | type 2 diabetes mellitus | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT01073852 Comparator | Jun 2011 → Jun 2012 | chronic urticaria | Vanderbilt University | Withdrawn | No outcome recorded |
| — | NCT00405275 Comparator | Jul 2007 → Dec 2011 | rheumatoid arthritis | US Department of Veterans Affairs | Completed | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-19 | Novartis Pharmaceuticals | Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts novartis.com ↗ |
| 2020-04-20 | Novartis Pharmaceuticals | Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients novartis.com ↗ |
| 2020-04-10 | Sanofi | COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries sanofi.com ↗ |
| 2020-03-20 | Novartis Pharmaceuticals | Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response novartis.com ↗ |
| 2020-03-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide tevapharm.com ↗ |
| 2020-03-03 | Novartis Pharmaceuticals | International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa novartis.com ↗ |
| 2018-04-17 | Novartis Pharmaceuticals | Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials novartis.com ↗ |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 523 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydroxychloroquine | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗473“The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and...” NCT04353037 ↗ “Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR...” NCT03411798 ↗ “The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and...” NCT04441424 ↗ “The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary...” NCT03822780 ↗ “csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗ “Eligible patients in group 2 will receive oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to...” NCT04349241 ↗ “Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.” NCT04502342 ↗ “Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)” NCT04809623 ↗ “Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma” NCT02013778 ↗ “hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.” NCT06949982 ↗ “The intervention group will be treated with 28 days Doxycycline 2 x 100 mg (standard of care) combined with hydroxychloroquine 2 x 200 mg (two time a day one tablet).” NCT07230028 ↗ “The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00531817 ↗ “Among the all the drugs being used for the treatment of COVID-19, hydroxychloroquine (HCQ), has given some rays of hope to battle against this deadly pandemic.” NCT04408456 ↗ “Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00720798 ↗ “methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months” NCT00908089 ↗ “DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death” NCT02470468 ↗ “Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc” NCT04475588 ↗ “methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily” NCT05671497 ↗ “HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization” NCT05113810 ↗ “HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization” NCT04731051 ↗ “Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response. Other Names: HCQ” NCT04976465 ↗ “hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.” NCT03660059 ↗ “Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)” NCT02219347 ↗ “Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01211834 ↗ “The group I received Sofosbuvir plus Ledipasvir and Group II received Oseltamivir, hydroxychloroquine "HCQ" plus Azithromycin.” NCT04530422 ↗ “including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony” NCT04066803 ↗ “Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine” NCT01313208 ↗ “Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.” NCT03400865 ↗ “2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.” NCT03289403 ↗ “The goal of this clinical trial is to learn if drug hydroxychloroquine works to treat steatohepatitis in adults.” NCT07265297 ↗ “DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01256736 ↗ “Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus” NCT04374903 ↗ “Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days” NCT04528927 ↗ “To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin.” NCT04395170 ↗ “umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine” NCT04501783 ↗ “conventional DMARD (hydroxychloroquine or sulfasalazine) plus methotrexate for 24 weeks.” PMID 27006728 ↗ Feb 2016 “Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days” NCT04374539 ↗ “Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours” NCT04331470 ↗ “Hydroxychloroquine is a drug that has been used to treat malaria and rheumatism.” NCT01292408 ↗ “Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery” NCT04275778 ↗ “Hydroxychloroquine will be strongly recommended for all the patients.” NCT04702256 ↗ “Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids” NCT01491815 ↗ “chloroquine 500 mg, 1x2/day or hydroxychloroquine cp 200 mg, 1x2/day” NCT04475120 ↗ “methotrexate, leflunomide, hydroxychloroquine or sulfasalazine” NCT05447520 ↗ “methotrexate, leflunomide, hydroxychloroquine or sulfasalazine” NCT03863405 ↗ “Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks.” NCT02551575 ↗ “methotrexate- leflunomide- sulfasalazine- hydroxychloroquine” NCT06640309 ↗ “Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.” NCT04434248 ↗ “methotrexate, sulfasalazine, plus hydroxychloroquine” NCT01015547 ↗ “Hydroxychloroquine 400 mg only on the first day” NCT04463420 ↗ “additional sulfasalazine and hydroxychloroquine” PMID 22464340 ↗ Mar 2012 “Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d” NCT02842814 ↗ “Hydroxychloroquine 200 mg Twice daily” NCT01870128 ↗ “hydroxychloroquine (200mg tablets)” NCT04304053 ↗ “Hydroxychloroquine (e.g. Quensyl®)” NCT02779114 ↗ “Drug: Hydroxychloroquine Sulfate” NCT04491994 ↗ “hydroxychloroquine (plaquenil®)” NCT06753565 ↗ “Hydroxychloroquine Monotherapy” NCT04358081 ↗ “Drug: Hydroxychloroquine” NCT04668469 ↗ “Hydroxychloroquine” NCT06389201 ↗ |
| Known as | Antimalarials | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093765 ↗ |
| Known as | CASnr 118-42-3 (hydroxychloroquine); 737-36-4 (hydroxychloroquine sulfate) | “CASnr 118-42-3 (hydroxychloroquine); 737-36-4 (hydroxychloroquine sulfate)” NCT01207739 ↗ |
| Known as | Dolquine | “Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine® tablet) daily the first...” PMID 32727613 ↗ Jul 2020 |
| Known as | Ercoquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | Fenle | “Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above.” NCT06652113 ↗ |
| Known as | HCQ | “The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo...” NCT04329923 ↗118“To characterize the effects of hydroxychloroquine (HCQ) on the modulation of markers of autophagy, as measured by p62, Beclin1, LC3, and GRp170 expression, in pre- and...” NCT00962845 ↗ “The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and...” NCT04353037 ↗ “We subsequently tested the effects of transient versus chronic inhibition of autophagy with chloroquine or hydroxychloroquine (HCQ) and mTOR signaling with rapamycin (RAPA) or...” PMID 40897974 ↗ Sep 2025 “The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory...” NCT04330495 ↗ “This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to...” NCT04384380 ↗ “Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by...” NCT05841758 ↗ “This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and...” NCT06971744 ↗ “The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine...” NCT04351919 ↗ “This is an exploratory, open label, multi-center study to evaluate the efficacy of hydroxychloroquine (HCQ) (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (AZT)...” NCT04329572 ↗ “OBJECTIVES: Primary Objective • To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete...” PMID 32493478 ↗ Jun 2020 “Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR...” NCT03411798 ↗ “To determine the safety of adding hydroxychloroquine (HCQ) to continuous low dose palbociclib and letrozole and to determine the recommended phase II dose (RP2D) for...” NCT03774472 ↗ “The use of hydroxychloroquine (HCQ) during pregnancies complicated by systemic lupus erythematosus or refractory antiphospholipid antibody syndrome has demonstrated a...” PMID 39658277 ↗ Dec 2024 “Trastuzumab Deruxtecan(T-DXd) or Sacituzumab Govitecan (SG) combined with hydroxychloroquine(HCQ) in the treatment of advanced breast cancer in clinical practice has the...” NCT06328387 ↗ “The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with...” NCT06479291 ↗ “Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the...” PMID 32674792 ↗ Jul 2020 “The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary...” NCT03822780 ↗ “Hydroxychloroquine (HCQ) has been shown to lower glucose levels in non-pregnant populations and has demonstrated safety in pregnant women with systemic lupus erythematosus and...” PMID 41558753 ↗ Jan 2026 “Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy...” PMID 39264960 ↗ Sep 2024 “This study is testing a medication, called hydroxychloroquine (HCQ) to assess safety and effectiveness to prevent individuals at risk of type 1 diabetes (T1D) from progressing...” NCT03428945 ↗ “The phase 1b study demonstrated no DLT in patients treated with hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg,...” PMID 39731909 ↗ Dec 2024 “The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant...” NCT03400865 ↗ “To assess the effectiveness and safety of hydroxychloroquine (HCQ) prophylaxis for the prevention of SARS-CoV-2 infection in healthcare workers (HCW) on duty during the...” PMID 36849996 ↗ Feb 2023 “This multicentre randomised controlled trial aimed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren's...” PMID 41423293 ↗ Dec 2025 “Participants will be provided with weekly dosing of hydroxychloroquine (HCQ) 400mg po q weekly, daily dosing of HCQ 200mg po q daily following a loading dose of 400mg day 1, or placebo.” NCT04341441 ↗ “The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known.” PMID 34251903 ↗ Jul 2021 “This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP).” NCT04120883 ↗ “Hydroxycholoroquine (HCQ) is an inexpensive anti-malarial drug with immunomodulatory effects that are currently used as an off-label treatment for symptomatic COVID-19 patients.” NCT04364815 ↗ “The aim of this proposed study is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in children's interstitial lung diseases(chILD) with genetic causes.” NCT04532346 ↗ “In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS).” PMID 36214614 ↗ Oct 2022 “Hydroxychloroquine (HCQ) is a medication commonly used in pregnancy to treat autoimmune and connective tissue diseases such as systemic lupus erythematosus (SLE).” NCT02379650 ↗ “4 weeks Hydroxychloroquine Sulfate (HCQ, Quensyl). First week loading dose 10 mg/kg bw/d, p.o., once daily in the evening, followed by 6.5 mg/kg bw/d for 3 weeks.” NCT02615938 ↗ “prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective in preventing SARS-CoV-2 infection progression” PMID 34344672 ↗ Aug 2021 “Among the all the drugs being used for the treatment of COVID-19, hydroxychloroquine (HCQ), has given some rays of hope to battle against this deadly pandemic.” NCT04408456 ↗ “the autophagy inhibitor: hydroxychloroquine (HCQ) and the autophagy inducer: sirolimus (rapamycin, Rapa) would reduce glucose utilization in sarcoma patients.” PMID 26375670 ↗ Oct 2015 “Among the various therapeutic strategies being tested, the use of hydroxychloroquine (HCQ) emerges as a viable option, albeit with limitations in the studies.” NCT04400019 ↗ “Determine the maximum tolerated dose of hydroxychloroquine (HCQ) in combination with temsirolimus (TEM) in patients with metastatic refractory solid tumors.” NCT00909831 ↗ “Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.” NCT02551575 ↗ “OBJECTIVE: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19).” PMID 32391667 ↗ May 2020 “The intervention involves hydroxychloroquine (HCQ), administered orally in 200 mg tablets, with a dosing schedule of 200 mg twice daily (400 mg per day).” NCT06816810 ↗ “Hydrochloroquine (HCQ, Plaquenil) is a CQ derivative with fewer side effects than CQ, which has long been used as anti-malarial and antirheumatoid agent.” NCT01292408 ↗ “AI-optimised combination drug regimen consisting of Pyrazinamide (PYZ) and Hydroxychloroquine (HCQ) for treating drug-sensitive pulmonary tuberculosis.” NCT07467252 ↗ “We evaluated the efficacy and safety of hydroxychloroquine (HCQ), an immunomodulator, when added to the treatment regimen of patients with IgAN.” PMID 30922594 ↗ Mar 2019 “The American Academy of Ophthalmology (2016-AAO) recommended hydroxychloroquine (HCQ) dose not to exceed 5 mg/kg/day (real body weight).” PMID 33486596 ↗ Jan 2021 “hydroxychloroquine (HCQ), an anti-malarial drug with immunomodulatory properties could potentially have a role as a third step treatment” NCT05737680 ↗ “To determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs).” PMID 36682681 ↗ Jan 2023 “Hydroxychloroquine (HCQ) is licensed for the chemoprophylaxis and treatment of malaria and as a disease modifying antirheumatic drug.” NCT04354870 ↗ “Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response. Other Names: HCQ” NCT04976465 ↗ “Hydroxychloroquine (HCQ) is a cheap anti-malarial and immunomodulatory agent which may potentially be used as PEP against COVID-19.” NCT04342156 ↗ “Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy.” PMID 24991840 ↗ May 2014 “Recent basic studies on orbital fibroblasts suggest hydroxychloroquine (HCQ) as a promising therapeutic agent for GO patients.” PMID 40760017 ↗ Aug 2025 “hydroxychloroquine (HCQ), a well-tolerated drug typically used in the prevention of malaria transmission and rheumatic disease” NCT04374942 ↗ “The experimental arm receiving Tab.Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400mg weekly for 11 weeks.” NCT04370015 ↗ “The third group will be given hydroxychloroquine (HCQ 400 mg/day) for five days plus the conventional treatment of covid-19.” NCT05311813 ↗ “Patients in the experimental group will be given a combined oral treatment of hydroxychloroquine (HCQ) and levothyroxine.” NCT06652113 ↗ “Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days.” NCT04347980 ↗ “Chloroquine and hydroxychloroquine (HCQ) are robust inducers of the tumor suppressor Par-4 secretion from normal cells.” PMID 30603055 ↗ May 2018 “Hydroxychloroquine (HCQ), an antimalarial drug with anti-inflammatory properties, is employed in rheumatic diseases.” PMID 26197707 ↗ Jul 2015 “Hydroxychloroquine (HCQ) is an immunomodulator used to treat rheumatoid arthritis and systemic lupus erythematosus.” PMID 34535165 ↗ Sep 2021 “Hydroxychloroquine (HCQ), a commonly used medicine early in RA, may play a role in improving insulin resistance.” NCT01132118 ↗ “OBJECTIVE: To determine the symptom-modifying effect of hydroxychloroquine (HCQ) in hand osteoarthritis (OA).” PMID 29125901 ↗ Aug 2018 “Such inhibitors include the anti-malarial drug chloroquine (CQ) and its derivative, hydroxychloroquine (HCQ).” NCT03513211 ↗ “Hydroxychloroquine (HCQ), an emerging chemoprophylaxis, which holds clinical and mechanistic plausibility” NCT04397328 ↗ “Hydroxychloroquine (HCQ), currently in usage for treatment of severe Coronavirus Disease 2019 (COVID-19)” NCT04438837 ↗ “including the drug Hydroxychloroquine (HCQ), which is mainly used for Rheumatoid Arthritis and Malaria” NCT04437693 ↗ “Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE).” PMID 23144449 ↗ Nov 2012 “Hydroxychloroquine (HCQ) is an antimalarial drug, also used to treat rheumatic diseases such as SLE.” NCT02595346 ↗ “oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization” NCT02013778 ↗ “There are few randomized studies evaluating hydroxychloroquine (HCQ) in non-hospitalized patients.” PMID 35262569 ↗ Feb 2022 “At the beginning of the pandemic, hydroxychloroquine (HCQ) was recommended for COVID-19 treatment.” PMID 38098221 ↗ Dec 2023 “Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days” NCT04528927 ↗ “Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of 4- amino quinoline compounds.” NCT03592823 ↗ “Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents.” NCT05113004 ↗ “Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin” NCT01272310 ↗ “Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.” NCT04569890 ↗ “Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy.” PMID 30898821 ↗ Mar 2019 “Hydroxychloroquine (HCQ) is an agent that has been widely used to treat malaria.” NCT01634893 ↗ “The effect of hydroxychloroquine (HCQ) on dry eye has not been fully determined.” PMID 27366013 ↗ Apr 2016 “Hydroxychloroquine (HCQ) blocks autophagy by blunting lysosomal acidification.” PMID 35552447 ↗ Sep 2022 “Hydroxychloroquine (HCQ) is widely used in patients with autoimmune diseases” PMID 26421409 ↗ Sep 2015 “Hydroxychloroquine (HCQ) 6.5 mg/kg/day (maximum 400 mg daily) for 24 months.” NCT06676384 ↗ “infliximab (IFX) versus sulfasalazine (SSZ) plus hydroxychloroquine (HCQ)” PMID 32433827 ↗ Aug 2021 “Hydroxychloroquine (HCQ) has a variable effect on cholesterol synthesis.” PMID 38487037 ↗ Mar 2024 “The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion” NCT02910076 ↗ “monotherapy with hydroxychloroquine (HCQ) at their assigned dose level” NCT04163107 ↗ “MTX + sulfasalazine (SSZ) + hydroxychloroquine (HCQ) triple therapy” PMID 27483410 ↗ Jan 2017 “Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2.” PMID 34037911 ↗ May 2021 “Hydroxychloroquine (HCQ)in combination with Binimetinib (B).” NCT04735068 ↗ “Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.” NCT02079077 ↗ “with 400mg hydroxychloroquine (HCQ), taken orally once daily” NCT04352946 ↗ “hydroxychloroquine (HCQ) is 600 mg orally every 12 hours” NCT02257424 ↗ “Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis” NCT07265297 ↗ “Name of IMP: Hydroxychloroquine sulfate (HCQ); Quensyl.” NCT04342221 ↗ “baricitinib + hydroxychloroquine (HCQ) with HCQ alone” PMID 36793118 ↗ Feb 2023 “Hydroxychloroquine (HCQ) may benefit these patients” PMID 40781621 ↗ Aug 2025 “hydroxychloroquine (HCQ), an inhibitor of autophagy” NCT00813423 ↗ “Drug: Hydroxychloroquin HCQ 200 mg, oral” NCT04359537 ↗ “hydroxychloroquine (HCQ/ Plaquenil)” NCT04316169 ↗ “inhalable hydroxychloroquine (HCQ)” NCT04477083 ↗ “Hydroxychloroquine (HCQ) 200mg/day” NCT04349228 ↗ “Drug: Hydroxychloroquine (HCQ)” NCT06862284 ↗ “Hydroxychloroquine (HCQ)” NCT04358068 ↗ “Hydroxychloroquine (HCQ)” NCT01506973 ↗ “Hydroxychloroquine (HCQ)” NCT03400254 ↗ “Hydroxychloroquine (HCQ)” NCT04384458 ↗ “Hydroxychloroquine (HCQ)” NCT04858633 ↗ “hydroxychloroquine "HCQ"” NCT04530422 ↗ “Hydroxychloroquine (HCQ)” NCT04522466 ↗ “hydroxychloroquine (HCQ)” NCT01206530 ↗ “Hydroxychloroquine (HCQ)” NCT03037437 ↗ “hydroxychloroquine (HCQ)” PMID 33681731 ↗ Feb 2021 “Hydroxychloroquine (HCQ)” NCT01897116 ↗ “hydroxychloroquine (HCQ)” NCT00714181 ↗ “Hydroxychloroquine (HCQ)” NCT05799378 ↗ “Hydroxychloroquine (HCQ)” NCT04369742 ↗ |
| Known as | Hidroxicloroquina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04330495 ↗ |
| Known as | Hydrochloroquine | “Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of 4- amino quinoline compounds.” NCT03592823 ↗1“Drug: Hydrochloroquine” NCT07265297 ↗ |
| Known as | Hydroxychloroquin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230028 ↗ |
| Known as | HYDROXYCHLOROQUINE Plaquenil | “HYDROXYCHLOROQUINE Plaquenil” NCT04341727 ↗ |
| Known as | Hydroxychloroquine sulfate | “This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to...” NCT04384380 ↗28“The investigational product hydroxychloroquine sulfate is a 4- aminoquinoline derivative and widely used for the treatment of many rheumatic diseases” NCT04411433 ↗ “Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above.” NCT06652113 ↗ “HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization” NCT05113810 ↗ “Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.” NCT04005768 ↗ “Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.” NCT03400865 ↗ “Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.” NCT04371523 ↗ “Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of 4- amino quinoline compounds.” NCT03592823 ↗ “Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg)” NCT04005781 ↗ “Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days” NCT04374539 ↗ “Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days.” NCT04354441 ↗ “Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days” NCT04371406 ↗ “Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.” NCT06519617 ↗ “Hydroxychloroquine sulfate (HCQ) is an inhibitor of autophagy” PMID 31120501 ↗ Jul 2019 “Treatment arm will be given Hydroxychloroquine sulfate.” NCT04342156 ↗ “Drug: Hydroxychloroquine Sulfate 400 mg twice a day” NCT04329923 ↗ “Hydroxychloroquine sulfate, also known as Plaquenil” NCT04374552 ↗ “Hydroxychloroquine Sulfate 200 MG [Plaquenil]” NCT04392128 ↗ “Hydroxychloroquine sulfate tablet” NCT04307693 ↗ “Hydroxychloroquine Sulfate (HCQ)” NCT04386057 ↗ “Drug: Hydroxychloroquine sulfate” NCT02615938 ↗ “Drug: Hydroxychloroquine Sulfate” NCT04341727 ↗ “Drug: Hydroxychloroquine Sulfate” NCT04354428 ↗ “Drug: Hydroxychloroquine Sulfate” NCT04371926 ↗ “Drug: Hydroxychloroquine Sulfate” NCT04316377 ↗ |
| Known as | Hydroxychloroquine Sulfate Tablets | “Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis” NCT06939582 ↗ |
| Known as | Hydroxychloroquine Sulphate | “Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks” NCT04359537 ↗1“Drug: Hydroxychloroquine sulphate” NCT04005781 ↗ |
| Known as | hydroxychloroquine(HCQ) | “hydroxychloroquine(HCQ)” NCT03411798 ↗ |
| Known as | Hydroxychloroquine; Plaquenil, RVG 00853 | “Hydroxychloroquine; Plaquenil, RVG 00853” NCT01207739 ↗ |
| Known as | hydroxycloroquina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669367 ↗ |
| Known as | NSC-4375 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | Oxiklorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | Plaquanil | “Hydroxychloroquine \[Plaquanil®\] is licensed to treat rheumatoid arthritis and other inflammatory conditions; it is related to the antimalarial chloroquine.” NCT01232660 ↗ |
| Known as | Plaquenil | “Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis” NCT05119140 ↗10“Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days.” NCT04354441 ↗ “The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab” NCT06229340 ↗ “Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)” NCT00946790 ↗ “Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days” NCT04371406 ↗ “Plaquenil (hydroxychloroquine) is an anti-malarial agent” NCT02126683 ↗ “Hydroxychloroquine sulfate, also known as Plaquenil” NCT04374552 ↗ “Hydroxychloroquine Sulfate 200 MG [Plaquenil]” NCT04392128 ↗ “hydroxychloroquine (Plaquenil) tablets” NCT00102557 ↗ “hydroxychloroquine (HCQ/ Plaquenil)” NCT04316169 ↗ “hydroxychloroquine (plaquenil®)” NCT06753565 ↗ |
| Known as | Plaquenil sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | PLAQUENILR | “Hydroxychloroquine (PLAQUENILR) is an orally available autophagy inhibitor that has been used for many years to treat autoimmune diseases like lupus, sarcoidosis and rheumatoid...” NCT03979651 ↗ |
| Known as | PlaquenilTM | “standard care with the addition of 400 mg hydroxychloroquine sulphate (PlaquenilTM) twice daily for seven days” PMID 32503662 ↗ Jun 2020 |
| Known as | Polirreumin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | Quensyl | “The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary...” NCT03822780 ↗2“Name of IMP: Hydroxychloroquine sulfate (HCQ); Quensyl.” NCT04342221 ↗ “Hydroxychloroquine (e.g. Quensyl®)” NCT02779114 ↗ |
| Known as | Quinoric | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | Sovuna | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | TCMDC-123987 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗ |
| Known as | Z0188 | “hydroxychloroquine (Z0188)” NCT01551069 ↗ |
| Known as | 硫酸羟氯喹 | “目的: 初步评价硫酸羟氯喹治疗2019冠状病毒病（COVID-19）普通型患者的疗效和安全性。” PMID 32391667 ↗ May 2020 |
| Action | Inhibit | “Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy.” PMID 24991840 ↗ May 2014 |
| Modality | Small molecule | “Hydroxychloroquine is an old chloroquine-derived drug, prescribed for auto-immune disorders.” NCT04347512 ↗ |
| Route | Oral | “receive oral hydroxychloroquine twice daily” NCT00031824 ↗ |
| Target | TLR7 | “Hydroxychloroquine is TLR7 and TLR9 antagonist.” NCT01601028 ↗ |
| Target | TLR9 | “Hydroxychloroquine is TLR7 and TLR9 antagonist.” NCT01601028 ↗ |